Hjem › Myelodysplastiske syndromer › South Carolina
Kliniske studier for Myelodysplastiske syndromer i South Carolina
7 studier for Myelodysplastiske syndromer søker deltakere på steder i South Carolina.
Byer i South Carolina
Offisiell studietekst (engelsk)
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Prisma Health Cancer Institute - Spartanburg, Boiling Springs
- Medical University of South Carolina, Charleston
- Prisma Health Cancer Institute - Easley, Easley
- og 5 flere
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 5. okt. 2026 · NCT05564390Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
- Prisma Health Cancer Institute - Spartanburg, Boiling Springs
- Prisma Health Cancer Institute - Easley, Easley
- Prisma Health Cancer Institute - Butternut, Greenville
- og 4 flere
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 5. okt. 2026 · NCT06577441The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Medical University of South Carolina, Charleston
- Prisma Health Richland Hospital, Columbia
- BI-LO Charities Children's Cancer Center, Greenville
RekruttererFase 1/2
Opp til 22 år · Alle kjønn · Oppdatert 25. aug. 2026 · NCT04726241Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
- Medical University of South Carolina, Charleston
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 15. jun. 2026 · NCT02074839A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Hollings Cancer Center, Charleston
RekruttererFase 2/3
Alder 18 og eldre · Alle kjønn · Oppdatert 30. apr. 2026 · NCT04256317A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Medical University of South Carolina, Charleston
RekruttererFase 1/2
Alder 12 og eldre · Alle kjønn · Oppdatert 24. mar. 2026 · NCT04988555SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Greenville
RekruttererObservasjonsstudie
Alle aldre · Alle kjønn · Oppdatert 28. okt. 2025 · NCT03452774Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.